HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leopold, N. A. Search for Related Content PubMed PubMed Citation Articles by Leopold, N. A.

Prolonged metoclopramideinduced dyskinetic reaction

From the Department of Neurology, Hahnemann University, Philadelphia, PA.

Metoclopramide is an effective non-phenothiazine antiemetic that acts, in part, by blockade of the dopamine receptors. The extrapyramidal complications of metoclopramide are similar to those of the phenothiazines. A patient is reported who developed a metoclopramideinduced acute dystonic reaction lasting 53 days. Acute and chronic treatment with anticholinergic drugs suppressed but did not eliminate the adventitious movements. The features of acute dystonic reactions secondary to metoclopramide therapy are reviewed.

Address correspondence and reprint requests to Dr. Leopold, DO, Division of Neurology, Crozer-Chester Medical Center, Chester, PA 19013.

Accepted for publication May 23,1983.

This article has been cited by other articles:

				D. D. Sewell and D. V. Jeste Metoclopramide-Associated Tardive Dyskinesia: An Analysis of 67 Cases Arch Fam Med, November 1, 1992; 1(2): 271 - 278. [Abstract] [PDF]

				L. G. Miller and J. Jankovic Metoclopramide-Induced Movement Disorders: Clinical Findings With a Review of the Literature Arch Intern Med, November 1, 1989; 149(11): 2486 - 2492. [Abstract] [PDF]

				R. H. Brown Jr, S. L. Hauser, H. Harrington, and H. L. Weiner Failure of Immunosuppression With a Ten- to 14-Day Course of High-Dose Intravenous Cyclophosphamide to Alter the Progression of Amyotrophic Lateral Sclerosis Arch Neurol, April 1, 1986; 43(4): 383 - 384. [Abstract] [PDF]